CAJ | 학술논문

2013年中国研发的7个新药品种被跨国制药公司收购，其中大部分处于临床前或临床试验阶段。本文通过调研分析这种情况的发生，认为一方面反映了中国新药研发能力逐步与国际接轨，得到了国际认可；另一方面也反映了中国医药产业整体竞争力仍与国际水平有很大差距。为此提出了培育大型龙头医药企业、对新药成果在本土企业的转让行为进行适度补贴方面加以引导、以及加大对人才培养和中小企业的支持等建议，以加强国内企业对新药成果转化应用。
2013년중국연발적7개신약품충피과국제약공사수구，기중대부분처우림상전혹림상시험계단。본문통과조연분석저충정황적발생，인위일방면반영료중국신약연발능력축보여국제접궤，득도료국제인가；령일방면야반영료중국의약산업정체경쟁력잉여국제수평유흔대차거。위차제출료배육대형룡두의약기업、대신약성과재본토기업적전양행위진행괄도보첩방면가이인도、이급가대대인재배양화중소기업적지지등건의，이가강국내기업대신약성과전화응용。
Seven new drugs innovated in China were acquired by multinational pharmaceutical companies in 2013,most of which were in pre-clinical or clinical research stage. This reflects that the current R&D capabilities of drug innovation in China have gradually caught up with the international standards and have been internationally recognized. On the other hand,it shows that there is still a big gap in the overall competitiveness of the pharmaceutical industry between China and the international counterparts. Some suggestions are proposed,including the cultivation of the leading pharmaceutical companies,the appropriate subsidies to domestic enterprises for new drug transformation,the improvement for personnel training and the supports to the small and medium enterprises.